More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications

The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market.

To order this 330+ page report, which features 130+ figures and 145+ tables, please visit this – https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

The USD 3.6 billion (by 2030) financial opportunity within the target protein degradation market has been analyzed across the following segments:

• Type of payment of licensing agreements
• Upfront payments
• Milestone payments

Type of protein degrader

• Degronimids
• PROTACs
• SARDs / SERDs
• Specific BET and DUB inhibitors
• Other protein degraders

Therapeutic area

• Neurodegenerative disorders
• Oncological disorders
• Other therapeutic areas

Route of administration

• Oral
• Intravenous
• Other routes

Key geographical region

• North America
• Europe
• Asia-Pacific

The Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030 report features the following companies, which we identified to be key players in this domain:

• Arvinas
• Captor Therapeutics
• Celgene
• Genetech
• Kymera Therapeutics
• Mission Therapeutics
• Progenra
• Radius Health
• Sanofi Genzyme
• Zenopharm

Table of Contents

1. Preface
2. Executive Summary
3. Introduction
4. Current Market Landscape
5. Company Profiles
6. Clinical Trial Analysis
7. KOL Analysis
8. Publication Analysis
9. Funding and Investment Analysis
10. Partnerships and Collaborations
11. Market Sizing and Opportunity Analysis
12. Executive Insights
13. Concluding Remarks
14. Appendix 1: Tabulated Data
15. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

Tags: Research, Protein, biotech, target, Rootsanalysis

The post More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications appeared first on Financial Market Brief.